Login    Join free Add to favorites    中文
home > news > AMSBIO: Experimental Cell Lines Help Screening for CAR T Therapies
Industry Updates | New Products | Supplier News | Upcoming Events | business | web
AMSBIO: Experimental Cell Lines Help Screening for CAR T Therapies

hits:98     Date:01/22/19
AMSBIO has added new experimental cell lines to its CAR T cell research range. 

Recent FDA approval of CAR T cells for treatment of leukemia and lymphoma has resulted in rapid growth in research on the therapeutic uses of such cells. The new AMSBIO experimental cell lines provide you with the power to screen antibodies and ligands against your target, enhancing your search for new CAR T therapies.

A therapeutic Chimeric Antigen Receptor (CAR) is a transmembrane protein designed with an extracellular domain based on an antibody single-chain variable fragment (scFv) and intracellular signaling domains derived from the TCR g chain, along with other costimulatory receptors. The scFv provides a specific binding domain that recognizes target proteins on cancer cells. A patient鈥檚 own T cells are isolated and activated, then transfected with a gene expressing the CAR. This reprograms the T cells to identify and attack tumor cells expressing the target protein, creating personalized immune cells designed to specifically target the patient鈥檚 cancer.

New stable CHO recombinant cell lines are available from AMSBIO for constitutively expressing full length human CD123, PSMA and ICOSL. Each stable clonal cell line was selected for different levels of expression to mimic different stages of cancer target cells with various CD123, PSMA or ICOSL expression levels.

At AMSBIO, we strive to provide tools at the cutting edge of cancer research. We produce a growing list of experimental cell lines, recombinant proteins and screening services to advance the search for new CAR T cell therapies. 

For further information on products and services for CAR T cell research please visit http://www.amsbio.com/car-t-cell-research.aspx  or contact AMSBIO on +44-1235-828200 / +1-617-945-5033 / info@amsbio.com. 

Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology. For further information please visit www.amsbio.com

Worldwide HQ 

AMS Biotechnology (AMSBIO)
184 Milton Park
Abingdon
Oxon OX14 4SE
UK
Tel: +44-1235-828200
Fax: +44-1235-820482
Email: info@amsbio.com 
Web www.amsbio.com
 
North American HQ
 
AMSBIO LLC
1035 Cambridge Street
Cambridge
MA 02141
USA
Tel: +1.617.945.5033 
Tel: +1.800.987.0985 (toll free)
Email: info@amsbio.com  
Web www.amsbio.com
Related News>> more
advertisement

Copyright(C) 2006-2019 Bio-Equip    E-mail:web@bio-equip.cn   娌狪CP澶06040519鍙